Alovudine - Misplaced Pages

Chemical compound Pharmaceutical compound

Alovudine
Clinical data

Other names	Fluorothymidine
ATC code	none
Identifiers
CAS Number	25526-93-6
PubChem CID	33039
ChemSpider	30578
UNII	PG53R0DWDQ
KEGG	D02830
ChEMBL	ChEMBL105318
CompTox Dashboard (EPA)	DTXSID4046579
Chemical and physical data
Formula	C₁₀H₁₃FN₂O₄
Molar mass	244.222 g·mol
3D model (JSmol)	Interactive image
SMILES O=C/1NC(=O)N(\C=C\1C)2O((F)C2)CO
InChI InChI=1S/C10H13FN2O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4H2,1H3,(H,12,15,16)/t6-,7+,8+/m0/s1 Key:UXCAQJAQSWSNPQ-XLPZGREQSA-N
(what is this?) (verify)

Alovudine (fluorothymidine) is an antiviral agent which was being developed by Medivir. It was discontinued after a Phase II trial in 2005 due to toxicity. It is a DNA polymerase inhibitor.

References

Georgopapadakou N (January 2007). "Discontinued drugs in 2005: anti-infectives". Expert Opinion on Investigational Drugs. 16 (1): 1–10. doi:10.1517/13543784.16.1.1. PMID 17155849. S2CID 24703317.

Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)

Capsid inhibitors

Lenacapavir (LEN)

Entry/fusion inhibitors
(Discovery and development)

Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))

Maturation inhibitors

Protease Inhibitors (PI)
(Discovery and development)

1 generation	Amprenavir (APV) Fosamprenavir (FPV) Indinavir (IDV) Lopinavir (LPV) Nelfinavir (NFV) Ritonavir (RTV) Saquinavir (SQV)
2 generation	Atazanavir (ATV)° Darunavir (DRV)° Tipranavir (TPV) TMC-310911

Reverse-transcriptase
inhibitors (RTIs)

Nucleoside and
nucleotide (NRTI)

Non-nucleoside (NNRTI)
(Discovery and development)

1 generation	Efavirenz (EFV) Nevirapine (NVP) Delavirdine (DLV)
2 generation	diarylpyrimidines Dapivirine (DPV) Etravirine (ETR) Rilpivirine (RPV) Doravirine (DOR) Elsulfavirine (ESV)

Combined formulations

Pharmacokinetic boosters

Experimental agents

Uncoating inhibitors	TRIM5alpha (gene)
Transcription inhibitors	Tat antagonists
Translation inhibitors	Trichosanthin
BNAbs	Elipovimab
Other	Abzyme BIT225 Calanolide A Ceragenin Cyanovirin-N Diarylpyrimidines Epigallocatechin gallate (EGCG) Foscarnet Fosdevirine Griffithsin Hydroxycarbamide KP-1461 Miltefosine Portmanteau inhibitors Scytovirin Seliciclib Synergistic enhancers Tre recombinase Zinc finger protein transcription factor
Failed agents	Aplaviroc Atevirdine Brecanavir Capravirine Dexelvucitabine Droxinavir Lasinavir Emivirine Lersivirine Lodenosine Loviride Mozenavir Palinavir Telinavir

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

°DHHS recommended initial regimen options. Formerly or rarely used agent.

DNA virus antivirals (primarily J05, also S01AD and D06BB)

Baltimore I

Herpesvirus

DNA-synthesis
inhibitor

TK activated

Purine analogue

adenine (Vidarabine)

Pyrimidine analogue

thymine

cytosine (Cytarabine)

Not TK activated

Foscarnet

Other

HPV/MC

Vaccinia

assembly: Rifampicin

Poxviridae

Hepatitis B (VII)

Multiple/general

Nucleic acid inhibitors	Cidofovir Brincidofovir
Interferon	Interferon alfa 2b Peginterferon alfa-2a
Multiple/unknown	Filociclovir Ribavirin/Taribavirin Moroxydine

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

RNA virus antivirals (primarily J05, also S01AD and D06BB)

Hepatitis C

NS3/4A protease inhibitors (–previr)	Asunaprevir Boceprevir Ciluprevir Danoprevir Faldaprevir Glecaprevir Grazoprevir Narlaprevir Paritaprevir Simeprevir Sovaprevir Telaprevir Vaniprevir Vedroprevir Voxilaprevir
NS5A inhibitors (–asvir)	Coblopasvir Daclatasvir Elbasvir Ledipasvir Odalasvir Ombitasvir Pibrentasvir Ravidasvir Ruzasvir Samatasvir Velpatasvir
NS5B RNA polymerase inhibitors (–buvir)	Beclabuvir Bemnifosbuvir Dasabuvir Deleobuvir Filibuvir GS-6620 IDX-184 Setrobuvir Sofosbuvir Tegobuvir TMC-647055 Radalbuvir Uprifosbuvir
Combination drugs	Elbasvir/grazoprevir Glecaprevir/pibrentasvir Ledipasvir/sofosbuvir Ombitasvir/paritaprevir/ritonavir Sofosbuvir/daclatasvir Sofosbuvir/velpatasvir Sofosbuvir/velpatasvir/voxilaprevir

Hepatitis D

Bulevirtide

Picornavirus

viral entry: Pleconaril

Anti-influenza agents

Multiple/general

Interferon	Interferon alfa 2b Peginterferon alfa-2a Peginterferon alfa-2b
3CL protease inhibitors (–trelvir)	Atilotrelvir Ensitrelvir Ibuzatrelvir Lufotrelvir Nirmatrelvir (+ritonavir) Rupintrivir Simnotrelvir (+ritonavir)
RNA pol inhibitors	CMX521 Deuremidevir Favipiravir Galidesivir GS-441524 Remdesivir MK-608 Mericitabine Molnupiravir NITD008 Ribavirin Taribavirin Triazavirin Valopicitabine
Multiple/Unknown/Other	EICAR Merimepodib Moroxydine Presatovir

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Categories:

See also

References